STC-15是一种强效、选择性、口服有效的RNA甲基转移酶METTL3抑制剂，IC50值为6.1nM。
Cas No.:2648257-56-9
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
STC-15 is a potent, selective and orally active inhibitor of RNA methyltransferase METTL3, with an IC50 value of 6.1nM [1]. STC-15 can activate the innate immune pathway and modify the tumor microenvironment (TME), transforming the TME from an immunosuppressive, tumor-promoting state to an immunostimulatory, anti-tumor state[2]. STC-15 has been widely used in inhibiting tumor progression in cell and animal models, as well as in the development of novel combined therapies[3].
In vitro, STC-15 treatment combined with HJP-178 for 7 days significantly inhibited the proliferation of SKOV-3 cells, with IC50 values of 1.194μM[4]. STC-15 treatment (0.5µM) for 48h induced the expression of endogenous IFN signaling in the Caov3 ovarian cell line[5].
In vivo, STC-15 treatment via intraperitoneal injection at a dose of 30mg/kg/day for 2 days significantly reduced the cellular level of m6A in peripheral blood mononuclear cells (PBMC) of SD rats[6].
References:
[1] Tang H, Zhang R, Zhang A. Small-molecule inhibitors targeting RNA m6A modifiers for cancer therapeutics: latest advances and future perspectives[J]. Journal of Medicinal Chemistry, 2025, 68(17): 18114-18142.
[2] Ofir-Rosenfeld Y, Vasiliauskaitė L, Obacz J, et al. Abstract C077: STC-15, a small molecule inhibitor of the RNA methyltransferase METTL3, activates anti-tumor immunity and reshapes the tumor microenvironment[J]. Molecular Cancer Therapeutics, 2023, 22(12_Supplement): C077-C077.
[3] Vasiliauskaite L, Ofir-Rosenfeld Y, Albertella M, et al. Abstract A18: STC-15, a novel METTL3 inhibitor, and its combination with Venetoclax confer anti-tumour activity in AML models[J]. Blood Cancer Discovery, 2023, 4(3_Supplement): A18-A18.
[4] Ou Y J, Liu B J, Xuan Y F, et al. The combination of BET and METTL3 inhibitors elicits synergistic antitumor effects in ovarian cancer cells via reducing SP1 and BCL-2 expression[J]. Life Sciences, 2025, 368: 123505.
[5] Ofir-Rosenfeld Y, Vasiliauskaitė L, Obacz J, et al. STC-15, a small molecule inhibitor of the RNA methyltransferase METTL3, activates anti-tumor immunity and reshapes the tumor microenvironment[C]//MOLECULAR CANCER THERAPEUTICS. 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA: AMER ASSOC CANCER RESEARCH, 2023, 22(12).
[6] Dutheuil G, Oukoloff K, Korac J, et al. Discovery, optimization, and preclinical pharmacology of EP652, a METTL3 inhibitor with efficacy in liquid and solid tumor models[J]. Journal of Medicinal Chemistry, 2025, 68(3): 2981-3003.
STC-15是一种强效、选择性、口服有效的RNA甲基转移酶METTL3抑制剂，IC50值为6.1nM[1]。STC-15可以激活先天免疫通路并改造肿瘤微环境（TME），将TME从免疫抑制、促肿瘤状态转变为免疫刺激、抗肿瘤状态[2]。STC-15已被广泛用于在细胞和动物模型中抑制肿瘤进展，以及用于开发新型联合疗法[3]。
在体外，STC-15联合HJP-178处理7天显著抑制了SKOV-3细胞的增殖，IC50值为1.194μM[4]。STC-15处理（0.5µM）48小时，在Caov3卵巢癌细胞系中诱导了内源性干扰素信号通路的表达[5]。
在体内，通过腹腔注射STC-15，剂量为30mg/kg/day，连续2天，显著降低了SD大鼠外周血单核细胞（PBMC）中的m6A水平[6]。
| Cell experiment [1]: | |
Cell lines | SKOV-3 cells |
Preparation Method | SKOV-3 cells were cultured in DMEM medium containing 10% fetal bovine serum (FBS) at 37℃ in the presence of 5% CO2. SKOV-3 (1500 cells/well) were seeded into six-well plates for the formation of colonies. Cells were cultured overnight and treated with different concentrations of STC-15 (1.562, 3.125, 6.25, 12.5, 25, and 50μM) for another 7 days. After being fixed, the cell colonies were stained with sulforhodamine B (SRB) and the numbers of colonies per well were counted. |
Reaction Conditions | 1.562, 3.125, 6.25, 12.5, 25, and 50μM; 7 days |
Applications | STC-15 treatment suppressed the cell proliferation of SKOV-3 cells in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | Male SD rats |
Preparation Method | Male SD rats were group-housed in cages with bedding material, and were housed in a room with controlled humidity (50±10%) and temperature (25±3°C) under a 12/12h light/dark cycle. All mice were adaptively fed for one week. The rats were intraperitoneally injected with 30mg/kg/day dose of STC-15 or 3mg/kg/day dose of EP652 for two days. PBMC samples were collected from the rats for analysis. |
Dosage form | 30mg/kg/day for 2 days; i.p. |
Applications | STC-15 treatment significantly reduced the cellular level of m6A in PBMCs of SD rats. |
References: | |
| Cas No. | 2648257-56-9 | SDF | |
| 分子式 | C24H25N5O2 | 分子量 | 415.49 |
| 溶解度 | DMSO : 116.67 mg/mL (280.80 mM; Need ultrasonic) | 储存条件 | -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4068 mL | 12.034 mL | 24.068 mL |
| 5 mM | 481.4 μL | 2.4068 mL | 4.8136 mL |
| 10 mM | 240.7 μL | 1.2034 mL | 2.4068 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet